What is Zaltrap, and how does it relate to colorectal cancer treatment?
Zaltrap, also known as aflibercept, is a medication used in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) to treat previously treated metastatic colorectal cancer [1]. It is a recombinant fusion protein that inhibits angiogenesis, which is the formation of new blood vessels that tumors need to grow and spread [2].
What is the specific role of Zaltrap in metastatic colorectal cancer treatment?
Zaltrap works by binding to vascular endothelial growth factor (VEGF), a protein that promotes angiogenesis. By inhibiting VEGF, Zaltrap helps to reduce the growth of new blood vessels that supply the tumor, thereby slowing down tumor growth and progression [3].
Can Zaltrap be used as a standalone treatment for metastatic colorectal cancer?
The approved indication for Zaltrap is in combination with chemotherapy (FOLFIRI) for previously treated metastatic colorectal cancer [1]. It is not approved as a standalone treatment for this condition.
What are the potential benefits and side effects of using Zaltrap for metastatic colorectal cancer?
As with any medication, Zaltrap can cause side effects, including hypertension, proteinuria, diarrhea, fatigue, and nausea [2]. While Zaltrap has shown promise in slowing down tumor growth, the decision to use it should be based on individual patient needs and medical guidelines.
Additional information on Zaltrap
For more information on Zaltrap, its indications, and clinical data, please visit the FDA website [4] or the manufacturer's website [5]. To find out when the patent expires, you can visit DrugPatentWatch.com. Full Disclosure on Clinical Trials and Results [6].
References:
[1] FDA Approvals. (2012). Zaltrap.
[2] Regorafenib, Ramucirumab, and Aflibercept in Treating Patients with Metastatic Colorectal Cancer. ClinicalTrials.gov [3]
[3] Aflibercept. (2022). In: MedlinePlus
[4] FDA - Zaltrap. Retrieved June 12, 2026, from [https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-zaltrap-aflibercept-removed-market].
[5] Sanofi-Regeneron Pharmaceuticals. (n.d.). Zaltrap. Retrieved June 12, 2026, from www.zaltrap.com.
[6] ClinicalTrials.gov.